Accenture estimates raised at UBS
ACN estimates increased through 2011, UBS said. F12 revenue and EPS guidance likely to be maintained. Maintain $64 price target and Buy rating.
-----
Adobe Systems estimates, target increased at Citigroup
Shares of ADBE now seen reaching $34, according to Citigroup. Estimates also raised as underappreciated secular value.
-----
Athenahealth downgraded at JP Morgan
ATHN was downgraded from Neutral to Underweight, JP Morgan said. Valuation call, based on a $50 price target.
-----
Bed, Bath & Beyond estimates raised at Sterne Agee
BBBY estimates were increased through 2012, Sterne Agee said. Company is cutting operating costs. Neutral rating.
-----
Boston Scientific rated new Hold at Kaufman
BSX was initiated with a Hold rating, Kaufman Bros. said. $7 price target. Company has still yet to show meaningful sales and earnings growth.
-----
Bristol-Myers upgraded at Goldman
BMY was upgraded from Neutral to Buy, Goldman Sachs said. $37 price target. Company has the best long-term earnings visibility in the group.
-----
Broadcom upgraded at JMP
BRCM was upgraded to Market Perform, JMP Securities said. Industry checks suggest better sales prospects.
-----
Conagra Foods rated new Hold at Jefferies
Coverage of CAG was started with a Hold rating, Jefferies said. $25 price target. Visibility is cloudy, given the failed RAH bid.
-----
Cubist Pharmaceuticals upgraded at BofA/Merrill
CBST was upgraded to Buy, Bank of America/Merrill Lynch said. $45 price target. Cubicin recently received a patent extension.
-----
CVS Caremark rated new Hold at Deutsche
Coverage of CVS was started with a Hold rating, Deutsche Bank said. Valuation call, based on a $38.50 price target.
-----
Deckers Outdoor rated new Buy at Auriga
Coverage of DECK was started with a Buy rating, Auriga said. $115 price target. Earnings expectations appear conservative for the near-term.
-----
Diamond Foods downgraded at Jefferies
DMND was downgraded to Hold, Jefferies said. Valuation call, based on a $94 price target.
-----
Dollar General rated new Buy at Guggenheim
DG was initiated with a Buy rating, Guggenheim said. $44 price target. Company should continue to expand its margins over the next several quarters.
-----
Edwards Lifesciences target upped at Jefferies
EW target was boosted to $94, Jefferies said. Company can generate significant earnings growth over the next few years.
-----
Family Dollar rated new Buy at Guggenheim
Coverage of FDO was started with a Buy rating, Guggenheim said. Company should continue to deliver solid growth and generate steady cash flow. $62 price target.
-----
Hershey rated new Hold at Jefferies
HSY was initiated with a Hold rating, Jefferies said. Valuation call, based on a $58 price target.
-----
HJ Heinz rated new Buy at Jefferies
HNZ was initiated with a Buy rating, Jefferies said. $59 price target. Company is leveraged to emerging market growth.
-----
Hologic rated new Buy at Kaufman
Coverage of HOLX was started with a Buy rating, Kaufman Bros. said. $19 price target. New products should help drive growth in the coming quarters.
-----
Intel upgraded at BofA/Merrill
INTC was upgraded to Buy, Bank of America/Merrill Lynch said. $27 price target. Estimates also boosted, as the company is seeing margin expansion.
-----
Intuit target boosted at Jefferies
Shares of INTU now seen reaching $55, according to Jefferies. Company can deliver double-digit organic annual sales growth in the coming years. Buy rating.
-----
Johnson & Johnson downgraded at Goldman
JNJ was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $74 price target.
-----
Las Vegas Sands estimates, target increased at Citigroup
Shares of LVS now seen reaching $59, according to Citigroup. Estimates also raised to reflect GGR trends and improved VIP outlook. Buy rating.
-----
Lennar upgraded at Citigroup
LEN was upgraded from Hold to Buy, Citigroup said. $22 price target. Attractive valuation and seasonal homebuilder benefits.
-----
Lululemon Athletica rated new Buy at Argus
LULU was initiated with a Buy rating, Argus Research said. $75 price target. Company can continue to deliver 30% annual sales growth.
-----
Mako Surgical cut from Conviction Buy List at Goldman
MAKO was removed from the Conviction Buy list, according to Goldman Sachs. Valuation call, based on a $44 price target.
-----
Netflix upgraded at UBS
NFLX was upgraded from Sell to Neutral, UBS said. $130 price target. Valuation at more reasonable level after correction.
-----
New York Times estimates, target lowered at UBS
Shares of NYT now seen reaching $7, according to UBS. Estimates also lowered on weaker than expected 3Q guidance. Neutral rating.
-----
Red Hat estimates, target raised at Citigroup
Shares of RHT now seen reaching $48, according to Citigroup. Estimates also increased on higher guidance. Buy rating.
-----
Red Hat estimates increased at Morgan Stanley
RHT estimates were raised through 2013, Morgan Stanley said. Billings growth is accelerating. Overweight rating and $50 price target.
-----
Red Hat estimates increased at UBS
RHT estimates increased through 2013, UBS said. Strength across all metrics. Maintain $54 price target and Buy rating.
-----
Salesforce.com estimates cut at Jefferies
CRM estimates were reduced through 2012, Jefferies said. Assistly acquisition will dilute near-term earnings. Buy rating and $156 price target.
-----
St. Jude rated new Buy at Kaufman
Coverage of STJ was started with a Buy rating, $50 price target. Company is taking market share, but overall business growth is slowing.
-----
Stryker rated new Buy at Kaufman
SYK was initiated with a Buy rating, Kaufman Bros. said. $57 price target. Company has multiple growth drivers and should continue to generate solid cash flow.
-----
Tesla Motors rated new Outperform at Baird
TSLA was initiated with an Outperform rating, Robert Baird said. $35 price target. Company continues to differentiate itself from the competition.
-----
Walgreens rated new Hold at Deutsche
WAG was initiated with a Hold rating, Deutsche Bank said. $38.50 price target. ESRX dispute could continue to hang over the stock.
-----
Yahoo upgraded at Stifel
YHOO was upgraded from Hold to Buy, Stifel Nicolaus said. $18 price target. Likelihood of a buyout has improved to 80%.
-----
Zimmer rated new Hold at Kaufman
ZMH was initiated with a Hold rating, Kaufman Bros. said. $57 price target. Orthopedic market has lackluster growth potential.
